Business Description
InMed Pharmaceuticals Inc
NAICS : 325410
SIC : 3741
ISIN : CA4576371062
Total Employee Number:
13Description
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.22 | |||||
Equity-to-Asset | 0.36 | |||||
Debt-to-Equity | 0.39 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -69.46 | |||||
Beneish M-Score | -8.39 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 65.8 | |||||
3-Year EPS without NRI Growth Rate | 66.5 | |||||
3-Year FCF Growth Rate | 67.6 | |||||
3-Year Book Growth Rate | -86 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.72 | |||||
9-Day RSI | 40.28 | |||||
14-Day RSI | 42.7 | |||||
3-1 Month Momentum % | -7.41 | |||||
6-1 Month Momentum % | 83.82 | |||||
12-1 Month Momentum % | -31.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.37 | |||||
Quick Ratio | 1.37 | |||||
Cash Ratio | 1.12 | |||||
Days Inventory | 243.74 | |||||
Days Sales Outstanding | 63.92 | |||||
Days Payable | 106.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -218 | |||||
Shareholder Yield % | 1.93 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 30.26 | |||||
Operating Margin % | -510.93 | |||||
Net Margin % | -647.42 | |||||
EBITDA Margin % | -551.91 | |||||
FCF Margin % | -449.76 | |||||
OCF Margin % | -449.76 | |||||
ROE % | -147.49 | |||||
ROA % | -120.09 | |||||
ROIC % | -322.05 | |||||
3-Year ROIIC % | 44.83 | |||||
ROC (Joel Greenblatt) % | -1072.33 | |||||
ROCE % | -131.96 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2.63 | |||||
PB Ratio | 6.42 | |||||
Price-to-Tangible-Book | 6.28 | |||||
EV-to-EBIT | -0.43 | |||||
EV-to-EBITDA | -0.46 | |||||
EV-to-Revenue | 2.52 | |||||
EV-to-Forward-Revenue | 0.01 | |||||
EV-to-FCF | -0.57 | |||||
| Price-to-Net-Current-Asset-Value | 9.42 | |||||
| Price-to-Net-Cash | 28.25 | |||||
Earnings Yield (Greenblatt) % | -232.56 | |||||
FCF Yield % | -121.97 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
InMed Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.654 | ||
| EPS (TTM) (€) | -2.683 | ||
| Beta | 1.7987 | ||
| 3-Year Sharpe Ratio | -0.38 | ||
| 3-Year Sortino Ratio | -0.7 | ||
| Volatility % | 136.26 | ||
| 14-Day RSI | 42.7 | ||
| 14-Day ATR (€) | 0.083519 | ||
| 20-Day SMA (€) | 1.1985 | ||
| 12-1 Month Momentum % | -31.32 | ||
| 52-Week Range (€) | 0.498 - 2.72 | ||
| Shares Outstanding (Mil) | 5.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
InMed Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
InMed Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2027-02-11 | In 152 days | ||
| General meeting for 2026 | 2026-12-17 16:00 | In 97 days | ||
| First quarter earnings results for 2027 | 2026-11-06 | In 55 days | ||
| Annual report for 2026 | 2026-09-09 | 1.14 (-2.56%) | ||
| Fourth quarter earnings results for 2026 | 2026-09-09 | 1.14 (-2.56%) | ||
| Third quarter earnings results for 2026 | 2026-05-06 | 0.62 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-02-11 | 0.84 (+9.87%) | ||
| General meeting for 2025 | 2025-12-17 16:00 | 1.08 (+8.54%) | ||
| First quarter earnings results for 2026 | 2025-11-06 | 1.42 (-2.07%) | ||
| Annual report for 2025 | 2025-09-23 | 1.85 (-1.60%) |
Show
Entries
InMed Pharmaceuticals Inc Frequently Asked Questions
What is InMed Pharmaceuticals Inc(STU:MWG)'s stock price today?
The current price of STU:MWG is €1.13. The 52 week high of STU:MWG is €2.72 and 52 week low is €0.50.
When is next earnings date of InMed Pharmaceuticals Inc(STU:MWG)?
The next earnings date of InMed Pharmaceuticals Inc(STU:MWG) is 2026-11-06 Est..
Does InMed Pharmaceuticals Inc(STU:MWG) pay dividends? If so, how much?
InMed Pharmaceuticals Inc(STU:MWG) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers